

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in the Hong Kong with limited liability)

(Stock Code: 648)

CHANGE IN SUBSCRIPTION PRICE UNDER THE RIGHTS ISSUE OF RUI KANG PHARMACEUTICAL GROUP LIMITED

On 10 July 2015, the Company acknowledged that the subscription price under the Rui Kang Rights Issue will be changed from the original HK\$0.29 per Rui Kang Rights Share to HK\$0.18 per Rui Kang Rights Share, and has also confirmed to Rui Kang and the Rui Kang Underwriter its obligations under the Undertaking in respect of the Rui Kang Rights Issue with the Adjusted Subscription Price will remain unchanged. The total consideration for the proposed subscription of 206,250,000 Rui Kang Rights Shares according to the Undertaking will be adjusted to approximately HK\$37.13 million.

Reference is made to the announcement (the “**Announcement**”) of the Company dated 11 June 2015 relating to the Company’s full participation in the Rui Kang Rights Issue. Unless the content otherwise requires, terms used in this announcement shall have the same meanings as those defined in the Announcement.

On 10 July 2015, the Company received a notification letter from Rui Kang and the Rui Kang Underwriter regarding the change in the subscription price under the Rui Kang Rights Issue from the original HK\$0.29 per Rui Kang Rights Share to HK\$0.18 per Rui Kang Rights Share (the “**Adjusted Subscription Price**”). The Company has confirmed to both Rui Kang and the Rui Kang Underwriter that its obligations under the Undertaking in respect of the Rui Kang Rights Issue with the Adjusted Subscription Price will remain unchanged. The total consideration for the proposed subscription of 206,250,000 Rui Kang Rights Shares on part of the Company under the Rui Kang Rights Issue will amount to approximately HK\$37.13 million.

Save for the change in subscription price under the Rui Kang Rights Issue as mentioned above, there is no other change in respect of the Company's participation in the Rui Kang Rights Issue under the Undertaking.

By Order of the Board of
China Renji Medical Group Limited
Chan Ka Chung
Chairman

Hong Kong, 10 July 2015

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo; and four independent non-executive Directors, namely, Mr. Chan Yee Ping, Michael, Mr. Lam Chun Ho, Ms. Hu Xuezhen and Ms. Wu Yan.